Originally inaugurated in 1968 by the Corbin brothers under the name of Therapex, E-Z-EM Canada Inc. (now BRACCO IMAGING Canada) quickly established itself with a solid reputation in the Canadian market for the development and manufacturing of liquids (solutions and suspensions), semi-solids (creams, ointments and gels), and powder blends.
A mere 2 years later, in 1970, expansion was on the horizon with the manufacturing of barium products for the Canadian market. In 1982 the company then unveiled a new modern factory occupying 22,000 square feet. Realizing that even further expansion was inevitable, the factory was further expanded by another 65,000 square feet, and began production and exportation of radiological products to Europe. The year 1995 brought further growth to the company with new barium suspensions being introduced to the worldwide market. With the strengthening the portfolio in the world over, Bracco Imaging Canada still maintains the highest quality of products and services to its clients.
HISTORY OF BRACCO IMAGING
Bracco Imaging S.p.A. is a worldwide provider of diagnostic imaging solutions.
Established in 1985 under the name Dibra Interchemical S.r.l. and incorporated in 1986 as Dibra S.p.A., the Company changed its name to Bracco Imaging S.p.A. in 2001 as an incorporated company controlled by Bracco S.p.A., the holding company of a multinational group active in the Healthcare Business which was originally founded in 1927.
Prior to that, all operations related to imaging agents were managed by Bracco without any dedicated company.
Bracco established its presence on the market with the launch of Iopamidol in 1981, the first and most widespread non-ionic contrast agent for X-Ray and CT procedures. Following the success met by Iopamidol, Bracco then ventured onto a path of international expansion that led to presence in the X-Ray/CT markets within the main geographical areas around the world.
Thanks to various acquisitions and strong innovation capabilities Bracco has strengthened its leadership in the areas of X-Ray/CT with Iomeprol. With the extension of its portfolio Bracco has expanded into the MRI market with ProHance® (gadoteridol) and MultiHance® (gadobenate dimeglumine), the Nuclear Medicine segment, and with a leading position in the fast growing niche areas of PET Cardiology and Hepatobiliary Imaging. Bracco continues to devote considerable effort and substantial resources to create and develop innovative products and solutions addressing unmet or poorly met medical needs.
In 2001 Bracco Imaging entered the innovative area of Contrast Ultrasound with the launch of SonoVue®, an ultrasound contrast agent consisting of microbubbles filled with Sulphur hexafluoride and stabilized by a flexible phospholipid shell.
Since the Nineties, the Company has begun a globalization process. Bracco Imaging today operates in over 90 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, licenses and distribution partnership agreements.
Bracco Imaging's portfolio was further broadened in April 2008 with the acquisition of E-Z-EM, Inc., a major manufacturer of contrast media and medical devices for gastrointestinal (GI) radiology and in 2011 with the acquisition of Swiss Medical Care, now Bracco Injeenering, which allowed Bracco to strengthen its portfolio of automated systems for the administration of contrast media.